Spago Nanomedical has achieved a significant milestone in its cancer therapy development journey. The company's drug candidate, 177Lu-SN201, has received approval to initiate the clinical phase I/IIa study, Tumorad-01, in Australia.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.283 SEK | -4.39% | -23.10% | -13.46% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.46% | 5.83M | |
-19.60% | 10.94B | |
+64.70% | 3.75B | |
-31.09% | 2.27B | |
-10.77% | 2.25B | |
-26.86% | 1.54B | |
+35.42% | 1.18B | |
-2.40% | 754M | |
-35.10% | 469M | |
+14.91% | 340M |
- Stock Market
- Equities
- SPAG Stock
- News Spago Nanomedical AB
- Spago Nanomedical Announces Cancer Therapy Approved for Phase I/IIa